Is the targeted approach for vitiligo satisfactory?

Vitiligo is also known as Safed Daagh, Kodh, Phuleri and Savitra in vernacular. causes social psychological distress, affecting 0.1 to 2 Percent global population. The pathology demonstrates depigmentation of the skin, with loss melanocytes by autoreactive cytotoxic T cells. vitiligo-infiltrating lymphocytes were lymphocytes, most CD8+The elevated levels H2O2 skin mediate production proinflammatory cytokines like IL-1β, IL6, IL-8 indirectly activating calreticulin pathway. Autoimmunity vitiligo driven IFN-γ-CXCL10 cytokine (motif chemokine ligand) signaling No drug can stop process vitiligo. Most drugs are used combination. Light therapy help restore some color. Topical steroids, calcineurin inhibitors, narrow-band ultraviolet (UV)–B phototherapy widely used. New depigmenting therapies emerging such helium-neon (He–Ne) lasers prostaglandin E2 analogs. In cases stable disease, surgical procedures grafting, blister orCellular suspension transplant often tried. Ruxolitinib first medication that pigment patients nonsegmental Tildrakizumab being evaluated form Cream. Unfortunately, life long condition which difficult treat satisfaction.